

Alexander R Vartanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/356269/publications.pdf>

Version: 2024-02-01

20
papers

2,439
citations

1307594

7
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

5301
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Cell</i> , 2013, 152, 714-726.	28.9	1,202
2	<i>SF3B1</i> and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2011, 365, 2497-2506.	27.0	1,021
3	Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage With Poor Skin Cancer Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2014, 150, 280.	4.1	83
4	Somatic mutation as a mechanism of Wnt/ β -catenin pathway activation in CLL. <i>Blood</i> , 2014, 124, 1089-1098.	1.4	65
5	Controversial fluorescence <i>in situ</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015, 170, 694-703.	2.5	19
6	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, , .	7.2	14
7	Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL. <i>Blood</i> , 2019, 134, 1745-1745.	1.4	8
8	Functional Somatic and Germline Variants in the NF- κ B Pathway in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 560-560.	1.4	7
9	NF- κ B Pathway Mutations Modulate Cell Survival and Ibrutinib Response In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 670-670.	1.4	5
10	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	1.3	3
11	Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101390.	0.4	3
12	High-grade heart block associated with ibrutinib therapy. <i>HeartRhythm Case Reports</i> , 2021, 7, 391-394.	0.4	3
13	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. <i>Blood</i> , 2018, 132, 4413-4413.	1.4	2
14	Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro. <i>Blood</i> , 2013, 122, 4132-4132.	1.4	2
15	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019, 134, 4291-4291.	1.4	1
16	The Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 5-5.	1.4	1
17	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 465-465.	1.4	0
18	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1438-1438.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3920-3920.	1.4	0
20	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4567-4567.	1.4	0